BioPerfectus

BioPerfectus supports the WHO’s global strategy to accelerate the elimination of Cervical Cancer.

The disease

KILLS MORE THAN

300,000

WOMEN EVERY YEAR

Annually, it is

DIAGNOSED IN OVER

600,000

Unless we take action, this preventable tragedy will only worsen.
If we accept the status quo,

BY 2030

annual

DEATHS WILL RISE TO

400,000

the annual number of new cases is projected to

INCREASE TO

700,000

90%

of girls fully vaccinated with HPV vaccine by age 15 years.

70%

of women are screened with a high-performance test by 35 years of age and again by 45 years of age.

90%

of women identified with cervical disease receive treatment (90% of women with precancer treated, and 90% of women with invasive cancer managed).

“This is a historic moment for global health. It marks the first time that the world has committed to eliminating a cancer.”

WHO Director-General, Dr Tedros Adhanom Ghebreyesus (17 November 2020)

Accelerating the Global Elimination of Cervical Cancer

Groundbreaking Technology

BioPerfectus globally groundbreaking quantitative HPV genotyping detection used for cervical cancer screening

60+ Countries and Regions

Supporting cervical cancer diagnosis and screening

10+ Million

HPV tests sold globally

Adhering to the concept of "embracing the world with health", BioPerfectus has developed a comprehensive solution for cervical cancer screening, aiming to accelerate the global elimination of cervical cancer.

This solution has tested over 10 million women, covering over 60 countries and regions worldwide.

It can be customized to meet various application scenarios:

The Quantitative HPV Genotyping Detection, designed for single-visit screening and optimization of HPV testing triage, brings higher cost efficiency.

The 16+2 high-risk testing option caters to large-scale population screening.

Integration with internet hospitals and self-sampling testing facilitates at-home testing, enhancing convenience and expanding the coverage of screening.

Globally Groundbreaking: Quantitative HPV Genotyping Detection

A

16

18

31
B

59

66

53
C

33

58

45
D

56

52

35
E

68

51

39
F

82

26

73
G

6

11

81
H

IC

Monitoring

Distingush transient and persistent HPV infection according to HPV genotyping and viral load changes.

Triage

Find the CIN2+ clinical cut-off value for HPV genotyping, promote lesion detection and reduce triage for colposcopy.

Predicting

HPV viral load has a predictive effect on the duration of persistent infection, pathogenicity,and the risk of cervical lesions.

Reminding

Monitoring the treatment of HPV infection, used as a predictor of residual lesions after CIN2+ treatment.

Leading new technologies to eliminate cervical cancer

·Multi-fluorescence quantitative PCR separately tube technology

·Normalized viral load determination: copies/ 10000 cells

·Consistent with the principle of a single-visit approach, reducing losses due
to triage and follow-up with higher cost efficiency

Primary Detection For Large-scale Population Screening

FAM

Detect HPV16

VIC

Detect HPV18

ROX

26 31 33 35 39 45 51 52 53 56 58 59 66 68 73 82

Detect other 16

HPV types

CY5

β-globin as

internal control

High Efficiency

Complete a batch of 96 tests within 2.5 hours
Multiple Types

Detect 18 high and intermediate-risk types, and differentiate between types 16/18 and other specified groups
Automation

Fully automated fluorescent quantitative PCR platform

Self-sampling To Privacy Protection

• Combine with Internet hospitals to bring convenience

• Expand the coverage of screening

• Storage and transportation at room temperature

• Mobile assistance transforms screening capacity in counties and promotes screening coverage

Why Should You Choose Our Comprehensive Cervical Cancer Screening Solution?

Fulfill Clinical Demands

Offering cervical swabs, liquid-based cytology samples, and self-sampling options

Trustworthy Performance

Reliable performance with high sensitivity and specificity validated

Support Flexible Operations

Walk-away system from VTM to PCR ready-to-go tubes, with one software for amplification, interpretation and customized report

Instruction For Use

Related Products

Human Papillomavirus Real Time PCR Kit

Cell Nucleic Acid Extraction Kit (Magnetic Bead Method)

Human Papillomavirus Genotyping Real Time PCR Kit

Automated Nucleic Acid Extraction Workstation SAW-48

Reference

1.Zhengrong Sun , Rong Zhang , Zhonghua Liu, Chao Liu, Xiulin Li, Weiqiang Zhou, Lianxia Yang, Qiang Ruan and Xu Zhang. Development of a fluorescence–based multiplex genotyping method for simultaneous determination of human papillomavirus infections and viral loads. BMC Cancer (2015) 15:860. doi 10.1186/s12885-015-1874-9 Available at: https://pubmed.ncbi.nlm.nih.gov/26546160/

2.Dong B, Sun P, Ruan G, Huang W, Mao X, Kang Y, Pan D, Lin F. Type-specific high-risk human papillomavirus viral load as a viable triage indicator for high-grade squamous intraepithelial lesion: a nested case- control study. Cancer Manag Res. 2018 Oct 23;10:4839-4851. doi: 10.2147/CMAR.S179724. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205532/

3.Chen L, Dong B, Zhang Q, Mao X, Lin W, Ruan G, Kang Y, Sun P. HR-HPV viral load quality detection provide more accurate prediction for residual lesions after treatment: a prospective cohort study in patients with high-grade squamous lesions or worse. Med Oncol. 2020 Mar 30;37(5):37. doi: 10.1007/s12032-020-01363-z. Available at: https://link.springer.com/article/10.1007%2Fs12032-020-01363-z

4.Duan L, Du H, Wang C, Huang X, Qu X, Shi B, Liu Y, Zhang W, Duan X, Wei L, Belinson JL, Wu R. The application of BMRT-HPV viral load to secondary screening strategies for cervical cancer. PLoS One. 2020 May 1;15(5):e0232117. doi: 10.1371/journal.pone.0232117. Available at: https://pubmed.ncbi.nlm.nih.gov/32357165/

5.Tao X, Zhang H, Wang S, Chen T, Cong Q, Wang L, Zhou X, Zhao C. Prevalence and carcinogenic risk of high-risk human papillomavirus subtypes in different cervical cytology: a study of 124,251 cases from the largest academic center in China. J Am Soc Cytopathol. 2021 Jul-Aug;10(4):391-398. doi: 10.1016/j.jasc.2021.03.006. Available at: https://www.sciencedirect.com/science/article/abs/pii/S2213294521000417

6.Li Y, Gong YX, Wang Q, Gao S, Zhang H, Xie F, Cong Q, Chen L, Zhou Q, Hong Z, Qiu L, Li F, Xie Y, Sui L. Optimizing the Detection of Occult Cervical Cancer: A Prospective Multicentre Study in China. 27 October 2021 Volume 2021:13 Pages 1005—1015. doi: 10.2147/IJWH.S329129 Available at: https://www.dovepress.com/optimizing-the-detection-of-occult-cervical-cancer-a-prospective-multi-peer-reviewed-fulltext-article-IJWH

7.Yiying Wang, Yan Wang, Michael M. Gaisa, Keith Sigel, Wenxin Zheng , Yuxin Liu , Yue Wang. Negative Predictive Value of Human Papillomavirus Testing: Implications for Anal Cancer Screening in People Living with HIV/AIDS. Journal of Oncology. 22 January 2020 Volume 2020 https://doi.org/10.1155/2020/6352315 Available at: https://www.hindawi.com/journals/jo/2020/6352315/

8.Feng?et?al. Human papillomavirus prevalence and genotype distribution landscapes in Shannan City, Tibet Tibetan Autonomous Region, China. Virology Journal (2022) 19:46 2022 Mar 18;19(1):46.?doi: 10.1186/s12985-022-01775-5 Available at: https://virologyj.biomedcentral.com/articles/10.1186/s12985-022-01775-5

9.Xiang Tao, Huina Zhang, Hao Zhang, Yaoxing Xiao, Fangfang Zhong, Xianrong Zhou, Qing Cong, Long Sui, Chengquan Zhao. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology A retrospective study of 8726 cases 2022 Mar 21.?doi: 10.1002/cncy.22573. Available at: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncy.22573

Eliminate Cervical Cancer

With BioPerfectus Cervical Cancer Screening Solution